Status:
UNKNOWN
Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia
Lead Sponsor:
Shanghai Public Health Clinical Center
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
HIV Infection
Hemophilia A
Eligibility:
All Genders
18-65 years
Brief Summary
This is an randomized, double-blind, placebo-controlled study to assess the safety, tolerability and efficacy of MK-0518 compared to placebo when combined with other antiretroviral drugs, in treatment...
Detailed Description
1. Objective To assess the safety, tolerability and efficacy of MK-0518 compared to placebo when combined with other antiretroviral drugs, in treatment-experienced HIV-infected patients with hemop...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- HIV-infected patients with hemophilia aged over 18 who have failed previous antiretroviral treatment are eligible.
Exclusion
Key Trial Info
Start Date :
May 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2011
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00797381
Start Date
May 1 2009
End Date
May 1 2011
Last Update
November 25 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Public Health Clinical Center
Shanghai, Jinshan, China, 201508